Researchers Offer New Insights into the Role of Tumor Necrosis Factor in IBD

Researchers Offer New Insights into the Role of Tumor Necrosis Factor in IBD
A study led by researchers at Children's Hospital Los Angeles recently revealed new insights into the role of tumor necrosis factor in the development of inflammatory bowel disease (IBD). The study was published in the journal Gastroenterology and is entitled “Tumor Necrosis Factor Receptor 2 Restricts the Pathogenicity of CD8+ T Cells in Mice With Colitis.” IBD is a chronic inflammatory condition of the digestive tract that primarily includes ulcerative colitis and Crohn’s disease. It is characterized by severe gastrointestinal symptoms, including vomiting, abdominal pain, rectal bleeding, diarrhea, internal cramps in the pelvis region, fatigue and weight loss. IBD can have a serious negative impact on the patient’s quality of life, and is known to increase the risk of colon cancer. It is estimated that more than one million individuals are living with IBD in the United States. It is unclear what triggers IBD, but the disorder is known to be associated to an immunological deregulation and a microbial imbalance in the gut. One common therapy for patients with moderate to severe IBD is based on the blockade of tumor necrosis factor (TNF), a molecule involved in systemic inflammation. However, anti-TNF therapies are only effective in one third of the IBD patients. TNF is recognized by two cell surface receptors – TNFR1 and TNFR2. The latter one is found primarily on immune cells, and its expression increases in intestinal epithelial cells during inflammation. In the study,
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *